Ketamine-like depression drug wins endorsement of key advisory panel

An experimental medication for depression related to the hallucinogenic street drug ketamine won a crucial endorsement from an independent advisory committee convened by the Food and Drug Administration on Tuesday.

In a 14-to-2 vote, the panel said the benefits of one step closer to approval.